HomeAI · summaries
Storia in 2 fonti
AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
AstraZeneca seeks a narrower path for failed antibody; Imfinzi and Tremfya label expansions
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
ICON audit finds overstated revenue; Secretome and Psilera raise cash
ICON audit found revenue was overstated in 2023 and 2024; Psilera and Secretome Therapeutics raise funds.
- ·
fiercepharma.com
AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday
- ·
AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
AstraZeneca seeks a narrower path for failed antibody; Imfinzi and Tremfya label expansions
- ·
ASCO: AstraZeneca's Imfinzi, Imjudo duo shines in earlier-stage liver cancer
AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new phase 3 readout from its Emerald trial program assessing…
- ·
Agios licenses Oscotec drug; CEPI funds three potential Ebola vaccines
Agios licenses Oscotec’s immune thrombocytopenia drug; CEPI funds three Ebola vaccine candidates; Skyhawk shares Huntington's data;